HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis OTC Habitrol Taking Private Label Tack

This article was originally published in The Tan Sheet

Executive Summary

Novartis Consumer Health is planning a "major" private label initiative with its newly approved OTC nicotine patches involving Wal-Mart, CVS and Walgreens. The firm intends to later market the product under its original Habitrol name, but the initial focus is in the private label setting. OTC Habitrol was approved Nov. 12.

You may also be interested in...

Novartis Tavist ND Loratadine Tablets Carry Geneva’s Marketing Exclusivity

Geneva Pharmaceuticals initially will market the first generic competition to Schering-Plough's OTC Claritin behind pharmacy counters

Novartis Habitrol Approval Marks First 3-In-1 Smoking Cessation Kit

Novartis Consumer Healthcare's Habitrol multi-dose smoking cessation kit will represent the first time an entire course of nicotine replacement therapy is available in a single package

Smoking Cessation Patch, Gum Prop 65 Warning Federally Preempted - Court

Requiring a special California Proposition 65 pregnancy warning on OTC nicotine-containing smoking cessation patches and gums would conflict with FDA requirements, a San Francisco state court judge has ruled.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts